This legislation mandates the Secretary of Health and Human Services (HHS) to issue comprehensive guidance to states within 180 days concerning the coverage of preeclampsia screening and early detection tests under the Medicaid and Children's Health Insurance Programs (CHIP). The guidance will outline best practices for improving outcomes for pregnant women with preeclampsia through early screening, detection, and management. It will also specify which tests, including advanced biomarker tests , may be furnished as medical assistance. Furthermore, the bill requires the Secretary to provide technical assistance to states within 30 days of a request, helping them determine coverage for specific preeclampsia detection tests. This assistance is not a prerequisite for states to cover such tests or receive federal financial participation. The aim is to enhance early diagnosis and management of preeclampsia, a condition contributing significantly to maternal and fetal mortality and morbidity, particularly among Black women and in high-risk populations.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Introduced in House
Referred to the House Committee on Energy and Commerce.
Health
PREEMPT Act
USA119th CongressHR-9061| House
| Updated: 5/29/2026
This legislation mandates the Secretary of Health and Human Services (HHS) to issue comprehensive guidance to states within 180 days concerning the coverage of preeclampsia screening and early detection tests under the Medicaid and Children's Health Insurance Programs (CHIP). The guidance will outline best practices for improving outcomes for pregnant women with preeclampsia through early screening, detection, and management. It will also specify which tests, including advanced biomarker tests , may be furnished as medical assistance. Furthermore, the bill requires the Secretary to provide technical assistance to states within 30 days of a request, helping them determine coverage for specific preeclampsia detection tests. This assistance is not a prerequisite for states to cover such tests or receive federal financial participation. The aim is to enhance early diagnosis and management of preeclampsia, a condition contributing significantly to maternal and fetal mortality and morbidity, particularly among Black women and in high-risk populations.